Hengyou Weng, Ph.D.
- Assistant Research Professor, Department of Systems Biology
Hengyou Weng, Ph.D.
Research Focus :
- Roles of m6A regulators in normal hematopoiesis and leukemogenesis
- Regulation of DNA demethylation in acute myeloid leukemia (AML)
- Targeted therapy for AML
Hengyou Weng obtained his Ph.D. from Sun Yat-sen University in China in 2012, where he studied the biological function of RNA G-quadruplex structure and the roles of microRNAs in chemoresistance in leukemia cells. He joined the lab of Jianjun Chen, Ph.D., in the University of Chicago in 2013 as a postdoctoral scholar and moved to University of Cincinnati with the lab at the end of 2014.
Weng focused on the biological consequences of DNA methylation and RNA methylation in acute myeloid leukemia. In 2017, he relocated to City of Hope with the Chen lab as an assistant research professor. Weng continues to study RNA epigenetics in AML and hopes to translate his research into clinical use.
- 2017 – Current, Assistant Research Professor, Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA
- 2014 – 2017, Postdoctoral Fellow, Department of Cancer Biology, University of Cincinnati, Cincinnati, OH
- 2013 – 2014, Postdoctoral Fellow, Department of Medicine, University of Chicago, Chicago, IL
- 2012, Ph.D., Biochemistry and Molecular Biology, Sun Yat-Sen University, China
- 2006, B.S., Biotechnology, Sun Yat-Sen University, China
Weng H*, Huang H*, Wu H*, Qin X*, Zhao BS*, Dong L*, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018; 22:191-205.
Huang H*, Weng H*, Sun W*, Qin X*, Shi H*, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu YC, Hüttelmaier S, Skibbe J, Su R, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan JL, He C, Yang J, Chen J. Recognition of RNA N6-methyadenosine by IGF2BP proteins enhances mRNA stability. Nat Cell Biol. 2018; 20:285-295.
Deng X, Su R, Weng H, Huang H, Li Z, Chen J. RNA N6-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018; 28:507-517.
Su R*, Dong L*, Li C*, Nachtergaele S*, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H, Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M, Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell. 2018; 172: 90-105.
Li Z*, Weng H*, Su R*, Weng X*, Zuo Z*, Li C, Huang H, Nachtergaele S, Dong L, Hu C, Qin X, Tang L, Wang Y, Hong GM, Huang H, Wang X, Chen P, Gurbuxani S, Arnovitz S, Li Y, Li S, Strong J, Neilly MB, Larson RA, Jiang X, Zhang P, Jin J, He C, Chen J. FTO Plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase. Cancer Cell. 2017; 31:127-141.
Jiang X*, Hu C*, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, Shen C, Arnovitz S, Ulrich B, Lu J, Weng H, Su R, Huang H, Wang Y, Li C, Qin X, Mulloy J, Zheng Y, Diao J, Jin J, Liu PP, Chen Y, Chen J. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017; 8: 2099.
Huang H*, Weng H*, Dong B, Zhao P, Zhou H, Qu L. Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia. Sci Rep. 2017; 7: 41525.
Wang Y, Skibbe JR, Hu C, Dong L, Ferchen K, Su R, Li C, Huang H, Weng H, Qin X, Jin J, Chen J, Jiang X. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia. Sci Rep. 2017; 7: 1853.
Jiang X*, Bugno J*, Hu C, Yang Y, Herold T, Qi J, Chen P, Gurbuxani S, Arnovitz S, Strong J, Ferchen K, Ulrich B, Weng H, Wang Y, Huang H, Li S, Neilly MB, Larson RA, Le Beau MM, Bohlander SK, Jin J, Li Z, Bradner JE, Hong S, Chen J. Eradication of acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles. Cancer Res. 2016; 76: 4470-4480.
Li Z*, Chen P*, Su R*, Hu C*, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J. PBX3 and MEIS1 cooperate in hematopoietic cells to drive acute myeloid leukemias characterized by a core transcriptome of the MLL-rearranged disease. Cancer Res. 2016; 76: 619-629.
Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, Weng H, Strong J, Wang Y, Li Y, Salat J, Li S, Elkahloun AG, Yang Y, Neilly MB, Larson RA, Le Beau MM, Herold T, Bohlander SK, Liu PP, Zhang J, Li Z, He C, Jin J, Hong S, Chen J. miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 2016; 7: 11452.
Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J. Identification of MLL-fusion/MYCimiR-26⊣TET1 signaling circuit in MLL-rearranged leukemia. Cancer Lett. 2016; 372: 157-165.
Weng H, Lal K, Yang F, Chen J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015, 208: 225-229.
Li Z*, Chen P*, Su R*, Li Y, Hu C, Wang Y, Arnovitz S, He M, Gurbuxani S, Zuo Z, Elkahloun AG, Li S, Weng H, Huang H, Neilly MB, Wang S, Olson EN, Larson RA, Le Beau MM, Zhang J, Jiang X, Wei M, Jin J, Liu PP, Chen J. Overexpression and knockout of miR-126 both promote leukemogenesis. Blood. 2015; 126: 2005-2015.
Weng H*, Huang H*, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res. 2014; 74: 4409-4419.
Huang H*, Weng H*, Zhou H, Qu L. Attacking c-Myc: targeted and combined therapies for cancer. Curr Pharm Des. 2014; 20: 6543-6554.
Weng HY*, Huang H*, Zhao P, Zhou H, Qu L. Translational repression of cyclin D3 by a stable G-quadruplex in its 5’ UTR: implications for cell cycle regulation. RNA Biol. 2012; 9: 1099-1109.
Huang H*, Weng H*, Wang L, Yu C, Huang Q, Zhao P, Wen J, Zhou H, Qu L. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther. 2012; 11: 1155-1165.
- American Society of Hematology
- 2016, American Society of Hematology Abstract Achievement Awards